Expanded Criteria for Liver Transplantation in Patients with Hepatocellular Carcinoma

被引:44
|
作者
Kim, J. M. [1 ]
Kwon, C. H. D. [1 ]
Joh, J. -W. [1 ]
Park, J. B. [1 ]
Lee, J. H. [2 ]
Kim, G. S. [3 ,4 ]
Kim, S. J. [1 ]
Paik, S. W. [2 ]
Lee, S. -K. [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Gastroenterol, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul 135710, South Korea
关键词
DONOR; SELECTION;
D O I
10.1016/j.transproceed.2013.11.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Liver transplantation (LT) is one of the few effective treatment options for hepatocellular carcinoma (HCC). Our aim in this study was to evaluate the risk factors for HCC recurrence and propose new criteria for LT based on pretransplantation findings. One hundred eighty patients who underwent LT for HCC between 2002 and 2008 were reviewed retrospectively. Outcome measures included maximal tumor size and number of tumors revealed by radiological studies before transplantation, demographics, and tumor recurrence. Maximal tumor size >6 cm, >7 tumors, and alpha-fetoprotein (APP) levels >1000 ng/mL were identified as independent prognostic factors of HCC recurrence in univariate and multivariate analysis. Disease-free survival rate in patients with a maximal tumor size <6 cm, <= 7 tumors, and/or AFP levels <= 1000 ng/mL at 1, 3, and 5 years was 97.9%, 91.5%, and 90.0%, respectively, but the 1-, 3-, And 5-year disease-free survival rate of patients who had a maximal tumor size >6 cm, >7 tumors, and/or APP levels >1000 ng/mL was 61.9%, 47.6%, and 47.6%, respectively (P < .001). In conclusion, LT can improve the survival of patients with advanced HCC if they have a maximal tumor size <= 6 cm, tumor number <= 7, and/or APP levels <= 1000 ng/mL.
引用
收藏
页码:726 / 729
页数:4
相关论文
共 50 条
  • [41] Prognostic Role of Plasma Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
    Zhang, Wei
    Kim, Richard
    Quintini, Cristiano
    Hashimoto, Koji
    Fujiki, Masato
    Diago, Teresa
    Eghtesad, Bijan
    Miller, Charles
    Fung, John
    Tan, Ann
    Menon, K. V. Narayanan
    Aucejo, Federico
    LIVER TRANSPLANTATION, 2015, 21 (01) : 101 - 111
  • [42] Recurrence After Liver Transplantation for Hepatocellular Carcinoma A New MORAL to the Story
    Halazun, Karim J.
    Najjar, Marc
    Abdelmessih, Rita M.
    Samstein, Benjamin
    Griesemer, Adam D.
    Guarrera, James V.
    Kato, Tomoaki
    Verna, Elizabeth C.
    Emond, Jean C.
    Brown, Robert S., Jr.
    ANNALS OF SURGERY, 2017, 265 (03) : 557 - 564
  • [43] Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma
    Grat, Michal
    Krawczyk, Marek
    Stypulkowski, Jan
    Morawski, Marcin
    Krasnodebski, Maciej
    Wasilewicz, Michal
    Lewandowski, Zbigniew
    Grat, Karolina
    Patkowski, Waldemar
    Zieniewicz, Krzysztof
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (13) : 4556 - 4565
  • [44] Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy
    Magyar, Christian Tibor Josef
    O'Kane, Grainne Mary
    Aceituno, Laia
    Li, Zhihao
    Vogel, Arndt
    Bruix, Jordi
    Mazzaferro, Vincenzo
    Sapisochin, Gonzalo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (05) : 589 - 604
  • [45] Short- and Long-Term Outcomes After Salvage Liver Transplantation Versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Meta-analysis
    Zhu, Y.
    Dong, J.
    Wang, W. -L.
    Li, M. -X.
    Lu, Y.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (09) : 3329 - 3342
  • [46] Survival outcomes of liver transplantation versus liver resection among patients with hepatocellular carcinoma: A SEER-based longitudinal study
    Zhang, Kai
    Chen, Ran
    Gong, Xumeng
    Gao, Yi
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (04) : 790 - 796
  • [47] Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis
    de Oliveira Vidal, Raphael Iglesias
    de Oliveira Vidal, Edison Iglesias
    Pereira, Basilio de Braganca
    Assane, Cachimo Combo
    Ribeiro, Alexandre
    do Nascimento, Emilia Matos
    Romeiro, Fernando Gomes
    Ribeiro Filho, Joaquim
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [48] Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Recurrence Characteristics and Risk Factors
    Li, Chuan
    Wen, Tian-Fu
    Liao, Zhi-Xue
    Yan, Lv-Nan
    Li, Bo
    Zeng, Yong
    Wang, Wen-Tiao
    Xu, Ming-Qing
    Yang, Jia-Ying
    Wei, Yong-Gang
    HEPATO-GASTROENTEROLOGY, 2010, 57 (99-100) : 567 - 570
  • [49] Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma
    Heits, Nils
    Brosch, Mario
    Herrmann, Alexander
    Behrens, Robin
    Roecken, Christoph
    Schrem, Harald
    Kaltenborn, Alexander
    Klempnauer, Juergen
    Kreipe, Hans-Heinrich
    Reichert, Benedikt
    Lenschow, Christina
    Wilms, Christian
    Vogel, Thomas
    Wolters, Heiner
    Wardelmann, Eva
    Seehofer, Daniel
    Buch, Stephan
    Zeissig, Sebastian
    Pannach, Sven
    Raschzok, Nathanael
    Dietel, Manfred
    von Schoenfels, Witigo
    Hinz, Sebastian
    Teufel, Andreas
    Evert, Matthias
    Franke, Andre
    Becker, Thomas
    Braun, Felix
    Hampe, Jochen
    Schafmayer, Clemens
    TRANSPLANTATION, 2018, 102 (10) : E424 - E430
  • [50] Should the Liver Transplant Criteria for Hepatocellular Carcinoma Be Different for Deceased Donation and Living Donation?
    Grant, David
    Fisher, Robert A.
    Abecassis, Michael
    McCaughan, Geoffrey
    Wright, Linda
    Fan, Sheung-Tat
    LIVER TRANSPLANTATION, 2011, 17 : S133 - S138